What's Going On With Novavax Stock Today?
What's Going On With Novavax Stock Today?
Novavax Inc (NASDAQ:NVAX) shares are trading higher Monday after Shah Capital Management reported a 6.66% stake in the company and nominated two directors for the company's board.
週一，Novavax Inc（納斯達克股票代碼：NVAX）股價上漲，此前沙阿資本管理公司報告持有該公司6.66％的股份，並提名了該公司董事會的兩名董事。
What Happened: In a new regulatory filing, Shah Capital, which owns 9.3 million shares of Novavax representing a 6.66% stake in the company, expressed disappointment with the recent performance of Novavax stock and appointed two new directors to the company's board.
發生了什麼：在一份新的監管文件中，擁有Novavax930萬股股份（佔該公司6.66％的股份）的Shah Capital對Novavax股票最近的表現表示失望，並任命了兩名新董事爲公司董事會成員。
The U.S.-based hedge fund said it believes its board nominees will bring the necessary experience to turn around the underperformance of the business and share price.
這家總部位於美國的對沖基金表示，它相信其董事會候選人將帶來必要的經驗，以扭轉業務和股價表現不佳的局面。
"Over a period of more than a year, Shah Capital has engaged repeatedly with the board and made several suggestions aimed at addressing self-inflicted problems which have undermined the success and sustainability of the company. However, the board has regrettably been unresponsive," Shah Capital said.
“在一年多的時間裏，Shah Capital多次與董事會接觸，並提出了幾項建議，旨在解決自己造成的問題，這些問題破壞了公司的成功和可持續性。但是，遺憾的是，董事會沒有做出回應。” 沙阿資本說。
"Following this subsequent inaction by Novavax, which is now trading at a near record low and is one of the most shorted stocks on the Nasdaq, Shah Capital has been forced to make public its concerns and call for leadership change."
“繼Novavax隨後無所作爲之後，Shah Capital被迫公開其擔憂並呼籲更換領導層，該公司目前的交易價格接近歷史新低，是納斯達克上空次數最多的股票之一。”
Shah Capital has recommended the appointment of Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of AI healthcare company Quantiva Health.
Shah Capital建議任命生物技術公司Saama的創始人兼首席執行官蘇雷什·卡塔和人工智能醫療公司Quantiva Health的首席執行官文卡特·佩裏。
The hedge fund said it believes Novavax needs to adopt a more dynamic sales and marketing strategy, targeting key Covid segments. Shah Capital also believes Novavax should turn its Matrix-M adjuvant franchise's inactive pipeline candidates into active opportunities through outside capital infusion and focus on efficient and effective spending in order to create operational profitability.
該對沖基金表示，它認爲Novavax需要採取更具活力的銷售和營銷策略，以Covid的關鍵細分市場爲目標。Shah Capital還認爲，Novavax應通過外部資本注入，將其Matrix-M輔助特許經營權不活躍的候選產品轉化爲積極的機會，並專注於高效和有效的支出，以創造運營盈利能力。
"It is unfathomable that given the sheer size of Novavax's unique market opportunity that the present team was only able to achieve ~200,000 jabs nationwide in Fall 2023 season," Shah Capital said.
沙阿資本表示：“鑑於Novavax獨特的市場機會的龐大規模，目前的團隊在2023年秋季只能在全國範圍內實現約20萬次疫苗，這是深不可測的。”
"This failure was not due to lack of demand, but instead was a function of marketing missteps, rollout issues and delays that simply would not happen with a sharper more focused team. Novavax can have over 50% covid market share this fall season if they play their cards right."
“這種失敗不是由於需求不足，而是由於營銷失誤、推出問題和延遲造成的，如果團隊更敏銳、更專注，這種情況根本不會發生。如果他們打對了牌，Novavax在今年秋季可以擁有超過50％的COVID市場份額。”
NVAX Price Action: Novavax shares were up 2.81% at $4.40 at the time of publication, according to Benzinga Pro.
NVAX價格走勢：根據Benzinga Pro的數據，Novavax股價在發佈時上漲2.81％，至4.40美元。
Photo: Marco Verch from Flickr.
照片： Marco Verch 來自 Flickr。
譯文內容由第三人軟體翻譯。